Publications by authors named "Jochen Mainz"

Claim this Profile
T
The validated French CFAbd-Score reveals a lower burden of gastrointestinal symptoms in patients on Elexacaftor/Tezacaftor/Ivacaftor.
Isabelle Sermet-Gaudelus, Pauline Sadrieh, Anne Sophie Bonnel, Raphael Enaud, Nathalie Wizla, Jochen Georg Mainz

J Pediatr Gastroenterol Nutr· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the CFAbd-Score.kid, a Novel gastrointestinal patient reported outcome measure, specific for children with cystic fibrosis.
Pauline Sadrieh, Lilith Bechinger, Franziska Duckstein, Anton Barucha, Lutz Nährlich, Jochen G Mainz

J Cyst Fibros· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The novel CFAbd-Score.kid reveals a significant decline of abdominal symptoms in children with Cystic fibrosis aged 6 through 11 years on Elexacaftor/Tezacaftor/Ivacaftor - first results.
Jochen G Mainz, Pauline Sadrieh, Lilith Bechinger, Franziska Duckstein, Anton Barucha

J Cyst Fibros· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Antibiotic Therapy on the Upper Respiratory Tract and Gut Mycobiome in Patients with Cystic Fibrosis.
Cristina Zubiria-Barrera, Malena Bos, Robert Neubert, Jenny Fiebig, Michael Lorenz, Jochen G Mainz

J Fungi (Basel)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duodenal Ulcer in a Child With Cystic Fibrosis on Elexacaftor-Tezacaftor-Ivacaftor Therapy: A Casual Association or a Possible Adverse Event?
Vito Terlizzi, Martina Di Benedetto, Sara Renzo, Valeria Galici, Luca Scarallo, Jochen G Mainz

Clin Ther· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement of abdominal symptoms in people with Cystic Fibrosis during therapy with Elexacaftor/Tezacaftor/Ivacaftor brings gastrointestinal involvement into the paediatric pulmonologist's focus.
Pauline Sadrieh, Lutz Nährlich, Carsten Schwarz, Olaf Eickmeier, Patience Eschenhagen, Jochen G Mainz

Klin Padiatr· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cross-cultural adaptation and validation of the CFAbd-Score for gastrointestinal symptoms in patients with cystic fibrosis.
Flávia N S Infante, Elizete A Lomazi, Carlos Zagoya, Franziska Duckstein, Daniela O Magro, Jochen G Mainz

J Pediatr (Rio J)· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A longitudinal study assessing the impact of elexacaftor/tezacaftor/ivacaftor on gut transit and function in people with cystic fibrosis using magnetic resonance imaging (MRI).
Alexander Yule, Christabella Ng, Arantxa Recto, Florence Lockwood, Neele S Dellschaft, Jochen G Mainz

J Cyst Fibros· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[CF Lung Disease - a German S3 Guideline: Pseudomonas aeruginosa].
Carsten Schwarz, Jutta Bend, Helge Hebestreit, Michael Hogardt, Christian Hügel, Jochen G Mainz

Pneumologie· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[CF Lung Disease - a German S3 Guideline: Pseudomonas aeruginosa].
Carsten Schwarz, Jutta Bend, Helge Hebestreit, Michael Hogardt, Christian Hügel, Jochen G Mainz

Pneumologie· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years - The RECOVER study.
Jochen G Mainz, Karen Lester, Basil Elnazir, Michael Williamson, Ed McKone

J Cyst Fibros· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considerations for the use of inhaled antibiotics for in people with cystic fibrosis receiving CFTR modulator therapy.
Pierre-Régis Burgel, Manfred Ballmann, Pavel Drevinek, Harry Heijerman, Andreas Jung, Jochen G Mainz

BMJ Open Respir Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Scoring Abdominal Symptoms in People with Cystic Fibrosis.
Harold Tabori, Anton Barucha, Carlos Zagoya, Franziska Duckstein, Gabor A Dunay, Jochen G Mainz

J Clin Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic rhinosinusitis in people with CF, a rapidly changing field.
Jochen G Mainz, Franziska Duckstein, Carlos Zagoya, Assen Koitschev

J Cyst Fibros· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes: a pilot study.
Christabella Ng, Neele S Dellschaft, Caroline Hoad, Luca Marciani, Robin Spiller, Jochen G Mainz

NIHR Open Res· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis.
Michael Wilschanski, Anne Munck, Estefania Carrion, Marco Cipolli, Sarah Collins, Jochen G Mainz

Clin Nutr· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire.
Jochen G Mainz, Anton Barucha, Pu Huang, Lilith Bechinger, Franziska Duckstein

Front Pharmacol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proliferative activity of antigen-specific CD154+ T cells against bacterial and fungal respiratory pathogens in cystic fibrosis decreases after initiation of highly effective CFTR modulator therapy.
Patience N Eschenhagen, Petra Bacher, Claudia Grehn, Jochen G Mainz, Alexander Scheffold

Front Pharmacol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined multi-channel intraluminal impedance measurement and pHmetry in the detection of gastroesophageal reflux disease in children with cystic fibrosis.
Emília da Silva Gonçalves, José Dirceu Ribeiro, Fernando Augusto Lima Marson, Ciro Garcia Montes, Antônio Fernando Ribeiro, Jochen Georg Mainz

J Pediatr (Rio J)· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score.
Jochen G Mainz, Carlos Zagoya, Louise Polte, Lutz Naehrlich, Lenny Sasse

Front Pharmacol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antigen specificity and cross-reactivity drive functionally diverse anti-Aspergillus fumigatus T cell responses in cystic fibrosis.
Carsten Schwarz, Patience Eschenhagen, Henrijette Schmidt, Thordis Hohnstein, Christina Iwert, Jochen G Mainz

J Clin Invest· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Cystic Fibrosis Upper and Lower Airway Metagenome.
Katarzyna Pienkowska, Marie-Madlen Pust, Margaux Gessner, Svenja Gaedcke, Ajith Thavarasa, Jochen G Mainz

Microbiol Spectr· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Divergent dynamics of inflammatory mediators and multiplex PCRs during airway infection in cystic fibrosis patients and healthy controls: Serial upper airway sampling by nasal lavage.
Nina Erdmann, Theresa Schilling, Julia Hentschel, Thomas Lehmann, Philipp von Bismarck, Jochen G Mainz

Front Immunol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elevated Levels of Toxic Bile Acids in Serum of Cystic Fibrosis Patients with Mutations Causing Pancreatic Insufficiency.
Harold Tabori, Jochen Schneider, Stefan Lüth, Carlos Zagoya, Anton Barucha, Jochen G Mainz

Int J Mol Sci· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The potential of volatile organic compound analysis for pathogen detection and disease monitoring in patients with cystic fibrosis.
Anton Barucha, Renan M Mauch, Franziska Duckstein, Carlos Zagoya, Jochen G Mainz

Expert Rev Respir Med· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis